PRODUCTOS DE LA NATURALEZA Y EL CASO ASSOCIATION FOR MOLECULAR PATHOLOGY V. MYRIAD GENETICS, INC.
- Published in:
- Propiedad Inmaterial, 2013, n. 17, p. 263
- By:
- Publication type:
- Article
Works matching Association for Molecular Pathology v. Myriad Genetics Inc.
Results: 20
1
2
ASSOCIATION FOR MOLECULAR PATHOLOGY V. MYRIAD GENETICS, INC. AND ITS IMPACT ON THE PATENTABILTY OF "DESIGNER" GENES.
- Published in:
- Journal of Intellectual Property & Entertainment Law, 2014, v. 4, n. 1, p. 37
- By:
- Publication type:
- Article
3
Association for Molecular Pathology v Myriad Genetics Inc: Are Genes Information or Molecules?
- Published in:
- Sydney Law Review, 2014, v. 36, n. 3, p. 557
- By:
- Publication type:
- Article
4
GENE PATENTS IN THE WAKE OF ASSOCIATION FOR MOLECULAR PATHOLOGY V MYRIAD GENETICS, INC.: AN INTERNATIONAL PERSPECTIVE ON PHARMACOGENOMICS.
- Published in:
- Cardozo Journal of International & Comparative Law, 2014, v. 23, n. 1, p. 99
- By:
- Publication type:
- Article
5
ROLLING WITH THE PUNCHES SINCE 1793: THE PATENT SYSTEM BEFORE AND AFTER ASSOCIATION FOR MOLECULAR PATHOLOGY V. MYRIAD GENETICS, INC., 133 S. CT. 2107 (2013).
- Published in:
- Southern Illinois University Law Journal, 2017, v. 41, n. 2, p. 305
- By:
- Publication type:
- Article
6
ASSOCIATION FOR MOLECULAR PATHOLOGY v. MYRIAD GENETICS, INC.: PROGRESS BY PRINCIPLES.
- Published in:
- Journal of Health Care Law & Policy, 2015, v. 18, n. 1, p. 141
- By:
- Publication type:
- Article
7
ASSOCIATION FOR MOLECULAR PATHOLOGY V. MYRIAD GENETICS, INC: WHAT ARE THE EFFECTS ON CLONING EXTINCT ANIMALS AND AGRICULTURE NOW THAT CDNA IS PATENTABLE?
- Published in:
- Drake Journal of Agricultural Law, 2014, v. 19, n. 3, p. 347
- By:
- Publication type:
- Article
8
FINAL REPORT OF THE BERKELEY CENTER FOR LAW & TECHNOLOGY SECTION 101 WORKSHOP: ADDRESSING PATENT ELIGIBILITY CHALLENGES.
- Published in:
- Berkeley Technology Law Journal, 2018, v. 33, n. 2, p. 551, doi. 10.15779/z38MW28F2T
- By:
- Publication type:
- Article
9
The Unpatentable Human Being.
- Published in:
- Hastings Center Report, 2013, v. 43, n. 5, p. 10, doi. 10.1002/hast.203
- By:
- Publication type:
- Article
10
The Human Patent: What Intellectual Property Rights Does an Individual Have in Their Own Genetic Material, and What Are the Global Biosecurity Implications?
- Published in:
- Journal of Biosecurity, Biosafety & Biodefense Law, 2021, v. 12, n. 1, p. 25, doi. 10.1515/jbbbl-2021-2002
- By:
- Publication type:
- Article
11
What the Supreme Court's Myriad Decision Means for Nanotechnology Patents.
- Published in:
- Nanotechnology Law & Business, 2013, v. 10, p. 132
- By:
- Publication type:
- Article
12
The Patent Eligibility of Graphene Claims Following the U.S. Supreme Court's Myriad Decision.
- Published in:
- Nanotechnology Law & Business, 2013, v. 10, p. 123
- By:
- Publication type:
- Article
13
AFTER PROMETHEUS, ARE HUMAN GENES PATENTABLE SUBJECT MATTER?
- Published in:
- Duke Law & Technology Review, 2013, v. 11, n. 2, p. 434
- By:
- Publication type:
- Article
14
Patenting nature—a comparative perspective.
- Published in:
- Journal of Law & the Biosciences, 2018, v. 5, n. 3, p. 550, doi. 10.1093/jlb/lsy021
- By:
- Publication type:
- Article
15
A Framework for Understanding Ethical and Efficiency Issues in Pharmaceutical Intellectual Property Litigation.
- Published in:
- Journal of Business Ethics, 2015, v. 132, n. 3, p. 505, doi. 10.1007/s10551-014-2365-7
- By:
- Publication type:
- Article
16
THE MYRIAD REASONS TO HIT "RESET" ON PATENT-ELIGIBILITY JURISPRUDENCE.
- Published in:
- Loyola of Los Angeles Law Review, 2013, v. 47, n. 1, p. 117
- By:
- Publication type:
- Article
17
LIFE, LIBERTY, AND THE PURSUIT OF GENETIC INFORMATION.
- Published in:
- Alabama Law Review, 2014, v. 65, n. 3, p. 625
- By:
- Publication type:
- Article
18
AFTER MYRIAD: RECONSIDERING THE INCENTIVES FOR INNOVATION IN THE BIOTECH INDUSTRY.
- Published in:
- Michigan Telecommunications & Technology Law Review, 2014, v. 21, n. 1, p. 141
- By:
- Publication type:
- Article
19
Patenting Genomics Innovations: Post-Myriad Challenges and Possibilities.
- Published in:
- Journal of Commercial Biotechnology, 2017, v. 23, n. 1, p. 55, doi. 10.5912/jcb773
- By:
- Publication type:
- Article
20
The Effects of Myriad and Mayo on Molecular-Test Development in the United States and Europe: Interviews from the Frontline.
- Published in:
- Vanderbilt Journal of Entertainment & Technology Law, 2020, v. 22, n. 4, p. 785
- By:
- Publication type:
- Article